As Congress considers the so-called "Clean Future Act," which would unfairly allow utilities to pass…
CFIF on Twitter CFIF on YouTube
Image of the Day: Electric Vehicle Irrationality

As Congress considers the so-called "Clean Future Act," which would unfairly allow utilities to pass the cost of electric vehicle charging stations that overwhelmingly benefit the rich to all utility customers, it's worth highlighting how even the New York Times acknowledges how impossible "Green New Deal" dreams for EVs really are:

[caption id="" align="aligncenter" width="501"] Impossible Electric Vehicle Dreams[/caption]

 …[more]

May 05, 2021 • 08:49 PM

Liberty Update

CFIFs latest news, commentary and alerts delivered to your inbox.
Jester's CourtroomLegal tales stranger than stranger than fiction: Ridiculous and sometimes funny lawsuits plaguing our courts.
CFIF Opposes State Attorneys General “March-In” Demand on Remdesivir Print
By CFIF Staff
Thursday, August 06 2020

ALEXANDRIA, VA – This week, a group of state attorneys general issued a joint letter to the United States Department of Health and Human Services (HHS), National Institutes of Health (NIH) and Food and Drug Administration (FDA) demanding that the federal government employ so-called “march-in” rights under the Bayh-Dole Act of 1980 to disregard Gilead Sciences, Inc.’s patent rights on its antiviral drug Remdesivir, or allow their states to do so.  The Center for Individual Freedom (CFIF) strongly opposes their demand.  

“If you seek to bring pharmaceutical innovation to a grinding halt, and deprive Americans of lifesaving drugs, the best way to do it is to flagrantly disregard patent protections for pharmaceutical innovators,” said Timothy Lee, CFIF’s Senior Vice President of Legal and Public Affairs.  “Unfortunately, that’s precisely the path that a misguided group of state attorneys general have decided to pursue.  Violating innovators’ patent rights won’t make drugs cheaper, it will only deprive consumers of potentially beneficial drugs entirely.  America currently produces two-thirds of all new drugs worldwide, and that’s because our nation honors and protects patent rights, it doesn’t violate them,” Lee added.    

“It’s particularly galling that the attorneys’ general seek to leverage the Bayh-Dole Act of 1980 to facilitate their scheme, and as we celebrate the law’s 40th anniversary to boot,” Lee continued.  “The Bayh-Dole Act was passed in order to extend patent rights to universities and nonprofit research entities whose research was assisted by federal funds, not weaken them.”  

Prior to Bayh-Dole, very few innovations partially funded by federal dollars were ever commercially pursued – only 390 in the year prior to its passage.  Forty years later, however, that number approaches 7,500, with over 420,000 inventions and 13,000 new startup enterprises formed.  

In the case of Remdesivir, Gilead Sciences has invested billions of dollars in research, development, testing and now manufacturing of the antiviral drug, including over $1 billion this year alone to expand manufacturing capacity both domestically and abroad.  Moreover, Remdesivir’s patents are held by Gilead Sciences, not other researchers or entities that received federal funding at various points in the drug’s creation and production.  Accordingly, Bayh-Dole doesn’t offer the legal means by which the attorneys general seek to achieve their counterproductive ends.  

Fortunately, HHS officials have expressed strict opposition to this scheme.  “CFIF strongly encourages the Trump Administration, HHS, NIH and FDA to maintain their rejection, and instead strengthen rather than limit patent rights for America’s world-leading pharmaceutical innovators, particularly in this time of critical societal need,” Lee concluded.  

CFIF is a constitutional and free market advocacy organization with over 300,000 supporters and activists nationwide.  

###

Quiz Question   
Based on the most recent U.S. Census Bureau data, which state lost the largest percentage of population in the last decade?
More Questions
Notable Quote   
 
"Missouri's chief legal disciplinary officer accused St. Louis' top prosecutor of sweeping misconduct in the failed prosecution of former Gov. Eric Greitens, saying she lied to judges in court filings and testimony, withheld exculpatory evidence from the defense, misled her own prosecution team and violated the constitutional right to a fair trial.St. Louis Circuit Attorney Kimberly Gardner, one of…[more]
 
 
—John Solomon, Just the News Editor in Chief
— John Solomon, Just the News Editor in Chief
 
Liberty Poll   

Are home prices in your immediate area rising, staying about the same or falling?